More on Avandia

Pharmalot is reporting today that, according to a study presented at the American College of Preventive Medicine annual meeting, a study of the reports on GlaxoSmithKline’s Avandia diabetes pill shows that reports authored with ties to the pharmaceutical industry were more likely to conclude the drug did not increase the risk of myocardial infarction compared with authors with no industry ties. Go here for the full story. Thanks to Pharmalot for the information.